To assess the efficacy and safety of sodium-glucose co-transporter 2 (SGLT2) inhibitors plus a dipeptidyl peptidase-4 (DPP-4) inhibitor in patients with type 2 diabetes mellitus (T2DM), we performed a systematic review and meta-analysis of 14 randomized controlled trials (RCTs) involving 4828 patients. Compared with a DPP-4 inhibitor, SGLT2 inhibitor/DPP-4 inhibitor combination therapy was significantly associated with a decrease in glycaemic control (HbA1c, −0.71%; fasting plasma glucose [FPG], −25.62 mg/dL; postprandial plasma glucose, −44.00 mg/dL), body weight (−2.05 kg) and systolic blood pressure (−5.90 mm Hg), but an increase in total cholesterol (TC) of 3.24%, high-density lipoprotein of 6.15% and lowdensity lipoprotein of 2.55%. Adding a DPP-4 inhibitor to an SGLT2 inhibitor could reduce HbA1c by −0.31%, FPG by −8.94 mg/dL, TC by −1.48% and triglycerides by −3.25%. Interestingly, low doses of an SGLT2 inhibitor in the combination has similar or even better efficacy in some aspects than high doses. Similar adverse events were observed for the combination therapy, with the exception of genital infection vs DPP-4 inhibitor (risk ratio 
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To assess the efficacy and safety of sodium-glucose co-transporter 2 (SGLT2) inhibitors plus a dipeptidyl peptidase-4 (DPP-4) inhibitor in patients with type 2 diabetes mellitus (T2DM), we performed a systematic review and meta-analysis of 14 randomized controlled trials inhibitors could suppress the production of endogenous glucose secondary to excess excretion of glucose from urine because they can inhibit glucagon and simulate insulin secretion. To qualitatively assess the efficacy and safety of SGLT2 inhibitor/DPP-4 inhibitor combination therapy vs SGLT2 inhibitor therapy or DPP-4 inhibitor therapy among patients with T2DM, we performed this systematic review and meta-analysis of available randomized controlled trials (RCTs) to provide evidence for clinical use of this combination therapy.
| MATERIALS AND METHODS
Available electronic databases from inception to June 14, 2017
were searched using relevant search terms (Table S1) 
| RESULTS
Fourteen studies involving 4828 patients were included in this metaanalysis ( Figure 1 ). Basic characteristics of the included studies and participants are presented in Table S2 . Risk of bias of the included RCTs is summarized in Figure S1 .
| Efficacy outcomes
Compared with a DPP-4 inhibitor, the combination therapy was sig- 
| Safety outcomes
Compared with a DPP-4 inhibitor, combination therapy was significantly associated with increased risk of genital infections (RR, 5.31; 95% CI, 1.39 to 20.32; I 2 = 40.2%) ( Table 1) . However, combination
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• PubMed (n=541)
• Cochrane Library (n=829)
• Embase (n=1,407) therapy seemed to be associated with a lower risk of consistent genital infections (RR, 0.61; 95% CI 0.39 to 0.96; I 2 = 0.0%) than an SGLT2 inhibitor (Table 1) . No significant difference was observed in the treatment-naïve subgroup based on one RCT (RR 0.92; 95% CI 0.43 to 1.97) (Table S4 ).
There was no other significant difference in adverse events including hypoglycaemia (definitions given in Table S7 ) between combination therapy and monotherapy, or between low and high doses of the SGLT2 inhibitor in combination therapy in primary (Table 1) or subgroup (Tables S3-S5 ) meta-analysis. HDL-C, which has a cardiovascular protective effect, was also increased in clinical trials, 9 as well as in our meta-analysis. However, the impact of increased fasting lipids on cardiovascular events in those patients remains unclear.
| DISCUSSION
Compared with SGLT2 inhibitors, this combination therapy also has beneficial effects on HbA1c, FPG, TC and TG. Similar to previous reviews, 10 our meta-analysis indicated that DPP-4 inhibitor/SGLT2
inhibitor combination therapy was associated with a lower risk of consistent genital infection. Although the underlying mechanism behind SGLT2 inhibitor-related genital infections remains unknown, pharmacologically-induced glucosuria may play a potential role by impairing host defense and/or increasing aldose reductase activity. 11, 12 It is logical to hypothesize that the reduction in the risk of consistent genital infection associated with combination therapy might be caused by relief of glucosuria by exerting a glucose-lowering effect when adding DPP-4 inhibitors to SGLT2 inhibitors, but more evidence is needed to confirm this.
Although the clinical impact remains unknown, our meta-analysis showed that low doses of an SGLT2 inhibitor in combination therapy was associated slightly but significantly with more reduction in body weight and DBP, and with less increase in TC and LDL-C. We acknowledge the following limitations. The major limitation of this meta-analysis was the limited number of included studies.
Although our research was comprehensive, based on eligible databases, only 14 RCTs were finally included, and there were even fewer RCTs for subgroup analysis. Secondly, there was significant heterogeneity among studies for specific comparisons, such as combination therapy vs DPP-4 inhibitor therapy concerning FPG and combination therapy vs SGLT2 inhibitor therapy concerning body weight.
Although subgroup meta-analysis was performed, the heterogeneity was still too high for confirmative conclusions.
In conclusion, compared with monotherapy, SGLT2 inhibitor/ DPP-4 inhibitor combination therapy was efficacious in treatmentnaïve patients or metformin-treated patients. However, this combination therapy might be associated with a higher risk of genital infections and increased levels of TC, HDL-C and LDL-C than those associated with a DPP-4 inhibitor. Low doses of an SGLT2 inhibitor might be prioritised when combination therapy is required. Further studies are warranted to confirm these conclusions.
